4basebio (LON:4BB) Receives Outperform Rating from Royal Bank of Canada

4basebio (LON:4BB)‘s stock had its “outperform” rating restated by equities research analysts at Royal Bank of Canada in a research note issued to investors on Thursday, MarketBeat.com reports. They presently have a GBX 1,600 ($20.70) price objective on the stock. Royal Bank of Canada’s price objective suggests a potential upside of 41.34% from the stock’s current price.

4basebio Price Performance

4basebio stock opened at GBX 1,132 ($14.64) on Thursday. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52. The company has a market capitalization of £145.01 million, a PE ratio of -1,451.28 and a beta of 1.09. 4basebio has a one year low of GBX 901 ($11.65) and a one year high of GBX 1,820 ($23.54). The business has a 50 day simple moving average of GBX 1,167.33 and a 200 day simple moving average of GBX 1,265.15.

Insider Buying and Selling at 4basebio

In other 4basebio news, insider Amy Walker acquired 1,151 shares of the business’s stock in a transaction on Friday, February 28th. The stock was purchased at an average price of GBX 1,120 ($14.49) per share, for a total transaction of £12,891.20 ($16,674.69). Corporate insiders own 68.44% of the company’s stock.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.